EAS Consulting Group is very pleased to welcome Tara Lin Couch, PhD, as the new senior adviser for dietary supplements.
Dr Couch is a PhD analytical/organic chemist with exceptional analytical abilities and more than 25 years of diverse laboratory and regulatory experience in academic, field, contract and manufacturing environments.
She is a sought after expert on issues pertaining to quality control in both pharmaceutical and dietary supplement manufacturing facilities, including the establishment of specifications and the development of well-organised, sophisticated laboratories.
As a consultant, Dr Couch has assisted numerous dietary supplement companies with the development, improvement and implementation of strong quality systems that are scientifically sound, efficient, practical and compliant with all FDA regulations. She also performs mock FDA inspections, gap-analyses and contractor facility audits. In addition, Dr Couch provides GMP and laboratory training via seminar, webinar and on-site presentations.
Dr Couch joins a team of EAS senior advisers who are leaders in their fields in developing regulatory compliant strategies, serving as expert witnesses and providing expert regulatory advice:
- John Bailey, Senior Adviser for Colours and Cosmetics
- Elizabeth Campbell, Senior Adviser for Labelling and Claims
- Anthony C. Celeste, Senior Adviser for Pharmaceutical Regulatory Affairs
- Nancy Chew, Senior Adviser for New Product Development and Submissions
- Susan Crane, Senior Adviser for OTC Drugs and Listings
- Robert L. Martin, Senior Adviser for Food and Colour Additive Safety
- William (Bill) Ment, Senior Adviser for GMP Audit Services
- Jeffrey Springer, Senior Adviser for FDA Regulatory and Legal Matters
- Stephen Sundlof, DVM, PhD, Senior Adviser for Animal and Human Food Safety.
Ed Steele, EAS Chairman and CEO and Dean Cirotta, President and COO are pleased that EAS continues to provide high level technical consultation for clients, and the appointment of Dr Couch to senior adviser, along with that of her fellow colleagues, sets EAS apart in its ability to provide pertinent leadership in the areas of FDA regulatory compliance.
